Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
July 18, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired.
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
July 16, 2024 08:05 ET
|
Organovo, Inc.
Organovo presented on the Company’s near and long-term outlook, operational plans, at the Jones Trading Healthcare Conference in Encinitas, CA.
Global Gut Microbiota Markets, Insights and Forecasts to 2031 - Key Players Danone, IFF, Ferring, and Nestle Focusing on R&D and Strategic Partnerships
July 12, 2024 05:35 ET
|
Research and Markets
Dublin, July 12, 2024 (GLOBE NEWSWIRE) -- The "Gut Microbiota Market, By Product, By Application, By Disease Type, By End Users, By Distribution Channel: By Region - Market Size, Industry Dynamics,...
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
July 08, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Event to highlight results from the clinical trial of BT-600, an orally administered drug-device combination in development for ulcerative colitis.
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
July 01, 2024 08:00 ET
|
Biora Therapeutics, Inc.
BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ability to deliver therapeutics directly to the colon
US Gastroenterologists Express Anticipation for Approval of AbbVie’s Skyrizi in Ulcerative Colitis, Projecting Rapid Adoption Post-Launch
June 12, 2024 12:18 ET
|
Spherix Global Insights
EXTON, PA, June 12, 2024 (GLOBE NEWSWIRE) -- Despite being the second IL-23 inhibitor to enter the market, AbbVie’s Skyrizi (risankizumab) is expected to have a substantial impact on ulcerative...
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
May 21, 2024 08:05 ET
|
Organovo, Inc.
Poster presented at DDW2024 demonstrating the potential of the Company’s clinical-stage compound, FXR314, in combination with tofacitinib for treating IBD.
Morphic Demonstrates Novel Real-Time Visualization of Small Molecule α4β7 Inhibition of Gut-Trafficking Cells
May 21, 2024 08:00 ET
|
Morphic Therapeutic
in vivo video presented at DDW 2024 show small molecule α4β7 inhibition rapidly increases rolling velocity & flux of B cells similar to antibodies
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
May 20, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Four device performance studies demonstrate the NaviCap platform’s ability to deliver therapeutics directly to the colon under variable GI conditions.
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
May 14, 2024 11:00 ET
|
Organovo, Inc.
Organovo will be presenting data on the Company’s lead clinical-stage drug, FXR314 during DDW2024, which is being held in Washington, D.C. May 18-21, 2024